Shire (LSE:SHP) Construction In Progress : £581 Mil (As of Sep. 2018)

View and export this data going back to 1996. Start your Free Trial

What is Shire Construction In Progress?

Shire's quarterly construction in progress increased from Mar. 2018 (£0 Mil) to Jun. 2018 (£591 Mil) but then declined from Jun. 2018 (£591 Mil) to Sep. 2018 (£581 Mil).

Shire's annual construction in progress increased from Dec. 2015 (£63 Mil) to Dec. 2016 (£2,109 Mil) but then declined from Dec. 2016 (£2,109 Mil) to Dec. 2017 (£1,916 Mil).

Shire Construction In Progress Historical Data

The historical data trend for Shire's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Construction In Progress Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Construction In Progress

Get a 7-Day Free Trial

27.82

28.05

62.59

2,108.63

1,915.88

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Construction In Progress	Get a 7-Day Free Trial															1,878.68	1,915.88	-	590.92	580.94

Shire Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Shire (LSE:SHP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (LSE:SHP) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Shire (LSE:SHP) Headlines

No Headlines